CN106459022B - 抗真菌化合物的制备方法 - Google Patents

抗真菌化合物的制备方法 Download PDF

Info

Publication number
CN106459022B
CN106459022B CN201580014312.0A CN201580014312A CN106459022B CN 106459022 B CN106459022 B CN 106459022B CN 201580014312 A CN201580014312 A CN 201580014312A CN 106459022 B CN106459022 B CN 106459022B
Authority
CN
China
Prior art keywords
mixture
alkyl
aryl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580014312.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459022A (zh
Inventor
威廉·J·胡克斯特拉
克里斯多夫·M·耶茨
马克·本克
阿萨夫·阿利马达诺夫
斯科特·A·大卫
道格拉斯·弗兰克林·弗莱依
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina - Yameite Pharmaceutical Co
US Department of Health and Human Services
Original Assignee
North Carolina - Yameite Pharmaceutical Co
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina - Yameite Pharmaceutical Co, US Department of Health and Human Services filed Critical North Carolina - Yameite Pharmaceutical Co
Publication of CN106459022A publication Critical patent/CN106459022A/zh
Application granted granted Critical
Publication of CN106459022B publication Critical patent/CN106459022B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Artificial Filaments (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201580014312.0A 2014-03-19 2015-03-19 抗真菌化合物的制备方法 Expired - Fee Related CN106459022B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955532P 2014-03-19 2014-03-19
US61/955,532 2014-03-19
PCT/US2015/021464 WO2015143154A1 (fr) 2014-03-19 2015-03-19 Procédé associé à un composé antifongique

Publications (2)

Publication Number Publication Date
CN106459022A CN106459022A (zh) 2017-02-22
CN106459022B true CN106459022B (zh) 2019-08-02

Family

ID=54145313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580014312.0A Expired - Fee Related CN106459022B (zh) 2014-03-19 2015-03-19 抗真菌化合物的制备方法

Country Status (12)

Country Link
US (2) US10077250B2 (fr)
EP (1) EP3119771B1 (fr)
JP (1) JP6606508B2 (fr)
KR (1) KR20160138013A (fr)
CN (1) CN106459022B (fr)
AU (1) AU2015231208B2 (fr)
BR (1) BR112016021282A8 (fr)
CA (1) CA2942930A1 (fr)
EA (1) EA201691648A1 (fr)
ES (1) ES2800905T3 (fr)
MX (1) MX369357B (fr)
WO (1) WO2015143154A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6606508B2 (ja) 2014-03-19 2019-11-13 マイコヴィア ファーマシューティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
CN109970629B (zh) * 2014-03-19 2023-04-11 迈科维亚医药公司 抗真菌化合物的制备方法
AU2015231216B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942936A1 (fr) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procede de preparation d'un compose antifongique
EP3119753B1 (fr) 2014-03-19 2020-11-04 Dow AgroSciences LLC 2-(2,4-difluorophényl)-1,1-difluoro-1-(pyridin-2-yl 5-substitué)-3-(1h-tétrazol-1-yl)propan-2-ols et procédés pour les préparer
JP2017509646A (ja) * 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231275B2 (en) 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
WO2015143184A1 (fr) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique
KR102441243B1 (ko) 2014-03-19 2022-09-07 브이피에스-3, 엘엘씨 2-(2,4-디플루오르페닐)-1,1-디플루오르-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
CN108289457B (zh) 2015-09-18 2021-08-06 迈科维亚医药公司 抗真菌化合物制备方法
BR112020009446A2 (pt) 2017-11-13 2020-11-03 Bayer Aktiengesellschaft derivados de tetrazólio propila e seu uso como fungicida
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097374A (zh) * 2010-04-24 2013-05-08 威尔金制药有限公司 金属酶抑制剂化合物
WO2013109998A1 (fr) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzymes
WO2013110002A1 (fr) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzyme

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
WO2010146113A1 (fr) 2009-06-18 2010-12-23 Basf Se Derives triazolyle antifongiques 1, 2, 4 ayant un substituant 5-soufre
KR20140040235A (ko) 2011-06-19 2014-04-02 비아멧 파마슈티컬즈, 인코포레이티드 금속효소 억제제 화합물
AU2012273100B2 (en) 2011-06-19 2017-05-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US8940735B2 (en) 2011-06-23 2015-01-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
IN2014MN01378A (fr) * 2011-12-11 2015-07-03 Viamet Pharmaceuticals Inc
US20150246898A1 (en) 2012-09-12 2015-09-03 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (fr) 2013-04-05 2014-10-09 The Regents Of The University Of California Couplage catalysé métallique d'halogénures d'aryle et de vinyle avec des composés alpha, alpha-difluorocarbonyle
US9447073B2 (en) * 2013-05-28 2016-09-20 Viamet Pharmaceuticals, Inc. Fungicidal compositions
AU2014278172B2 (en) 2013-06-12 2018-08-09 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2015143184A1 (fr) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procédé de préparation d'un composé antifongique
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231275B2 (en) 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942936A1 (fr) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Procede de preparation d'un compose antifongique
US9802914B2 (en) 2014-03-19 2017-10-31 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP6606508B2 (ja) 2014-03-19 2019-11-13 マイコヴィア ファーマシューティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231216B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
EP3119753B1 (fr) 2014-03-19 2020-11-04 Dow AgroSciences LLC 2-(2,4-difluorophényl)-1,1-difluoro-1-(pyridin-2-yl 5-substitué)-3-(1h-tétrazol-1-yl)propan-2-ols et procédés pour les préparer
KR102441243B1 (ko) 2014-03-19 2022-09-07 브이피에스-3, 엘엘씨 2-(2,4-디플루오르페닐)-1,1-디플루오르-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
CN109970629B (zh) * 2014-03-19 2023-04-11 迈科维亚医药公司 抗真菌化合物的制备方法
KR102603277B1 (ko) 2015-03-19 2023-11-17 마이코비아 파마슈티컬즈, 인코포레이티드 항진균성 화합물 및 이의 제조 방법
CR20170574A (es) 2015-05-18 2018-07-19 Viamet Pharmaceuticals Inc Compuestos antifíngicos
CN108289457B (zh) 2015-09-18 2021-08-06 迈科维亚医药公司 抗真菌化合物制备方法
AR106729A1 (es) 2015-11-17 2018-02-14 Viamet Pharmaceuticals Inc 4-((6-(2-(2,4-difluorofenil)-1,1-difluoro-2-oxoetil)piridin-3-il)oxi)benzonitrilo y proceso para su preparación
EP3377475A4 (fr) 2015-11-17 2019-04-10 Dow Agrosciences Llc 4-((6-2-(2,4-difluorophényl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile et procédés de préparation
EP3377480A4 (fr) 2015-11-17 2019-04-10 Dow AgroSciences LLC 4-((6-(2,4-difluorophényl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridine-3-yl)oxy)benzonitrile et procédés de préparation
TWI679198B (zh) 2015-11-17 2019-12-11 美商陶氏益農有限責任公司 製備４-（（６-（２-（２，４-二氟苯基）-１，１-二氟-２-羥基-３-（１ｈ-１，２，４-三唑-１-基）丙基）吡啶-３-基）氧基）苄腈之方法
EA038421B1 (ru) 2015-12-30 2021-08-26 ВиПиЭс-3, ИНК. Соединения, ингибирующие металлоферменты

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103097374A (zh) * 2010-04-24 2013-05-08 威尔金制药有限公司 金属酶抑制剂化合物
WO2013109998A1 (fr) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzymes
WO2013110002A1 (fr) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Composés inhibiteurs de métalloenzyme

Also Published As

Publication number Publication date
EA201691648A1 (ru) 2017-01-30
US20190177298A1 (en) 2019-06-13
BR112016021282A8 (pt) 2021-07-20
AU2015231208A1 (en) 2016-10-06
US10077250B2 (en) 2018-09-18
MX369357B (es) 2019-11-06
CN106459022A (zh) 2017-02-22
WO2015143154A1 (fr) 2015-09-24
ES2800905T3 (es) 2021-01-05
EP3119771A4 (fr) 2017-11-22
US20170144990A1 (en) 2017-05-25
BR112016021282A2 (fr) 2017-08-15
AU2015231208B2 (en) 2019-04-04
MX2016012053A (es) 2017-04-27
EP3119771A1 (fr) 2017-01-25
EP3119771B1 (fr) 2020-05-06
JP2017507993A (ja) 2017-03-23
JP6606508B2 (ja) 2019-11-13
KR20160138013A (ko) 2016-12-02
CA2942930A1 (fr) 2015-09-24

Similar Documents

Publication Publication Date Title
CN106459022B (zh) 抗真菌化合物的制备方法
US10836740B2 (en) Antifungal compound process
CN109970629B (zh) 抗真菌化合物的制备方法
AU2015231234B2 (en) Antifungal compound process
JP6572234B2 (ja) 抗真菌化合物の調製方法
AU2015231220B2 (en) Antifungal compound process
JP2017514790A (ja) 抗真菌化合物の調製方法
HK1234744B (zh) 抗真菌化合物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: North Carolina

Applicant after: VIAMET PHARMACEUTICALS, Inc.

Applicant after: U.S. Government Department of Health and Human Services

Address before: North Carolina

Applicant before: VIAMET PHARMACEUTICALS, Inc.

Applicant before: U.S. Government Department of Health and Human Services

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190802